ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1730

Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Abstract Number: 1731

A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
Abstract Number: 1732

Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Abstract Number: 1733

Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Abstract Number: 1734

Intra‑articular Liraglutide Halts Osteoarthritis Progression, Surpassing Dexamethasone in Synovial and Cartilage Protection
Abstract Number: 1735

Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Abstract Number: 1736

Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Abstract Number: 1737

CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
Abstract Number: 1738

Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes
Abstract Number: 1739

Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Abstract Number: 1740

A New Link Between Calprotectin, Cholesterol Efflux Dysfunction, and Premature Atherosclerosis in Juvenile Dermatomyositis
Abstract Number: 1741

Chronic JDM Plasma Proteomic Signature Reflects Inflammation from Immune and Tissue-resident Muscle and Skin
Abstract Number: 1742

S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Abstract Number: 1743

Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Abstract Number: 1744

Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].